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Cystic fibrosis: The ‘bicarbonate before chloride’ hypothesis
Jeffrey J. Wine
The specific effects of some mutations that cause cystic
fibrosis suggest that reduced HCO3– transport is the key
to understanding cystic fibrosis pathology. But there is
a puzzling discrepancy between measures of CFTR-
mediated chloride conductance in expression systems
and the sweat chloride values of patients.
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Cystic fibrosis is caused by the loss of function in the
‘cystic fibrosis transmembrane conductance regulator’ or
CFTR, an anion channel which is best known for con-
ducting chloride ions, but which also conducts bicarbon-
ate ions [1]. Among hundreds of mutations in the CFTR
gene that have been reported to cause cystic fibrosis, a few
appear to spare CFTR’s chloride channel function or even
produce channels with greater than normal chloride channel
activity [2–6]. Sixteen such mutations have now been
shown to disrupt CFTR’s mediation of bicarbonate trans-
port. Moreover, the degree to which the mutations reduce
bicarbonate transport is 100% predictive of whether patients
will lose pancreatic function. These remarkable findings,
reported recently by Shmuel Muallem and colleagues [7],
follow the same group’s earlier observation that CFTR
affects the electroneutral exchange of chloride and bicar-
bonate [8,9]. Together, the results lead Muallem and col-
leagues to conclude that restoration of chloride channel
function will not be sufficient to restore normal function to
individuals with cystic fibrosis.
The genetic disease cystic fibrosis involves mucus plugging
in the gastrointestinal, reproductive and respiratory tracts,
infection in the respiratory tract, and high sodium chloride
levels in the sweat. How are these defects related to simple
ions like chloride and bicarbonate? The currently prevalent
hypotheses all involve the role of CFTR-dependent ion
transport in moving salt and water across the mucosal
linings of affected organs. All affected organs in cystic fibro-
sis are exocrine, in the sense that their secretions eventually
exit the body, but the functions of the secretions differ
markedly. For example, sweat glands transport low-salt
water (~15–40 mM NaCl) onto the skin surface to provide
evaporative cooling, while the pancreas secretes digestive
enzymes in a bicarbonate-rich (~140 mM NaHCO3) fluid.
How do the results of Choi et al. [7] bear upon CFTR’s role
in the formation of sweat and pancreatic juice? CFTR
participates in each of these functions, but its role varies
strikingly in an organ-specific way. In the sweat duct,
CFTR is an ion channel for chloride and also activates an
associated epithelial sodium channel (ENaC) [10]. These
two apical channels, and associated basolateral transporters,
efficiently reabsorb sodium chloride from normal sweat; in
cystic fibrosis, the loss of functional CFTR directly elimi-
nates the apical chloride conductance and indirectly reduces
the apical sodium ion conductance, causing the NaCl levels
in sweat to approach plasma levels of >100 mM.
In the pancreatic duct, CFTR is essential for secretion of
the bicarbonate-rich fluid in which enzymes are carried.
Exactly how it accomplishes that task is still uncertain, but
much data fit a model in which bicarbonate is conducted
into the pancreatic lumen, probably through CFTR [11].
CFTR also appears to regulate chloride/bicarbonate exchan-
gers in the pancreatic membrane [8]. In any event, in the
pancreas the loss of CFTR function diminishes fluid secre-
tion to such an extent that the ducts become blocked, and
the pancreas is then destroyed and replaced by the fibrous
scar tissue that gives the disease its original full name:
cystic fibrosis of the pancreas.
With this background, let us return to the experiments
that are the main topic of this dispatch. Choi et al. [7]
expressed variously mutated forms of CFTR — the expres-
sion levels were quantified by co-expressing green fluores-
cent protein (GFP) — and then assayed the ability of the
transfected cells to transport chloride and bicarbonate
(Figure 1). They assessed chloride transport by loading
cells with the chloride-sensitive dye MQAE. The change
in the dye’s fluorescence was used to indicate chloride
efflux in response to forskolin stimulation in chloride-defi-
cient solutions. Untransfected cells have only a small con-
ductance to chloride that is distinguished from CFTR by
its insensitivity to forskolin.
It was not possible to measure bicarbonate transport
directly in human embryonic kidney cells, because in
these cells expression of CFTR did not produce a bicar-
bonate conductance, but instead enabled an electroneutral
transport mechanism that caused the internal pH to
increase when external chloride was decreased (with
replacement by NO3–). The most likely explanation of this
effect is that bicarbonate is being carried into the cell in
exchange for chloride. Untransfected cells or cells from
CFTR knockout mice do not show this effect, which is
activated, like CFTR itself, by forskolin. Hence the con-
clusion that CFTR activates an anion exchanger in the
membrane [8,9].
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When the 16 selected cystic-fibrosis-causing mutant forms
of CFTR were expressed, it was found that they all pro-
duced significant levels of chloride conductance, with 13
having equal or greater effects than wild-type CFTR.
That was expected, because most were selected precisely
because they had previously been shown to have that
feature [2–6]. In contrast, and unexpectedly, all of the
mutants generated reduced levels of bicarbonate transport,
and those with higher residual bicarbonate transport corre-
lated perfectly with an origin in patients who retained
residual pancreatic function. Based on these findings, Choi
et al. [7] concluded that CFTR’s ability to effect chloride
and bicarbonate transport are separable functions medi-
ated by different mechanisms, and that, at least for the
pancreas, CFTR-dependent bicarbonate transport is more
important than chloride conductance in predicting the
resulting pathology.
But what about the sweat duct? From the results of the
expression studies with these 16 mutations, both by Choi
et al. [7] and in earlier work [2–6], one would predict
normal, or at best mildly elevated, sweat NaCl levels in
subjects who have at least one of these mutations. That
follows because NaCl levels are normal for carriers — who
have 50% wild-type CFTR — and even for subjects who
have splicing mutations that reduce CFTR levels below
10% [12]. In contrast with that prediction, however, I was
able to obtain sweat chloride values for eight of the nine
mutations that produce pancreatic insufficiency, and found
that 100% of these occur in people who display the very
high (~100 mM) sweat chloride values that are diagnostic
for cystic fibrosis (see [7] for references to original reports).
That is true even for subjects who are homozygous for
mutations I148T [13] and G551D (R. Moss, personal com-
munication). Thus, the sweat chloride values are com-
pletely uncorrelated with the measured chloride transport
values of these mutations.
I was also able to obtain sweat chloride values for all four
of the cystic-fibrosis-causing mutations that are associated
with pancreatic sufficiency (this does not mean that the
pancreas is normal, rather that the residual secretion is
sufficient to prevent ductal blockage and degeneration),
and all of these are associated with levels of sweat NaCl
that are intermediate between normal values and those
associated with pancreatic insufficiency. The mean sweat
Cl– value for patients with these four mutations was
57 ± 17 mM. The point has been made previously that
pancreatic sufficient individuals, as a group, have lower
sweat Cl– values than pancreatic insufficient individuals
[14,15]. A fifth mutation, R1070Q, was originally reported
to be associated with a positive sweat test and both pancre-
atic sufficient and insufficient phenotypes. More complete
data indicate that R1070Q patients are pancreatic insuffi-
cient, with sweat chloride values >100 mM (Aleksey
Savov, personal communication). Finally, two other cystic
fibrosis mutations cited by Choi et al. [7], A800G and
E193K, occur in patients who have congenital bilateral
Figure 1
Results of Choi et al. [7], replotted to show
bicarbonate and chloride transport as a
percentage of wild-type (WT) values (dashed
line). Blue bars indicate bicarbonate transport;
mutations were ranked in descending order by
that property. The black and red bars indicate
chloride transport. Black bars indicate
intermediate sweat chloride values; red bars
are elevated sweat chloride values; the open
bar indicates an unreported value. The +
sweat chloride values are thought to be
~100 mM of chloride. The value given for
R117H is based on repeated measures of an
individual homozygous for that mutation (our
unpublished data). The numbers above each
of the bars indicate the measured sweat
chloride values for the subjects (in mM).
Based on the measured chloride transport for
these mutations, normal sweat chloride values
(20–40 mM) would be expected.
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absence of the vas deferens [16]. E193K occurs with the
severe mutation N1303K in a patient with ‘none of the
signs or symptoms of cystic fibrosis’, suggesting it is a very
mild mutation. A800G occurs with no other cystic fibrosis
mutation. Sweat tests were not performed for these patients,
however, so the status of these mutations as disease-causing
is uncertain.
It is not only sweat chloride values, however, that argue
against the thesis that chloride conductance is normal in
patients carrying these cystic-fibrosis-causing mutations.
The clinical status and cystic-fibrosis-related physiology of
a woman homozygous for the mutation G551S has been
described in detail [17]. Her sweat chloride value was
67 ± 4 mM, although surprisingly the potential difference
across her sweat ducts was in the normal range. But she
did not sweat in response to a β-adrenergic agonist, which
is characteristic for cystic fibrosis patients [18], and the
potential difference across her nasal mucosa was elevated
into the cystic fibrosis range (–50 mV) and displayed a low
chloride diffusion potential, as expected for an epithelium
with low chloride permeability [19]. Another perplexing
aspect of this work is the claim that CFTR appears to affect
only electroneutral transport of bicarbonate. Because CFTR
can conduct bicarbonate [1], it is puzzling that bicarbonate
conductance was not observed under the conditions of this
experiment.
In sum, although Choi et al. [7] stress the importance of
CFTR’s role in electroneutral bicarbonate transport and
the resulting fit with the severity of pancreatic disease, it is
at least as remarkable that their measures of CFTR-depen-
dent pHi change also correlate with NaCl levels in sweat,
whereas measures of CFTR-dependent chloride conduc-
tance in expression systems do not! That relationship
cannot be understood by their model, nor can the evidence
for low chloride permeability in the nasal epithelium of
the subject homozygous for the G551S mutation. Indeed,
no simple model seems capable of accommodating all of
the existing data, suggesting either that more than one
mechanism links CFTR mutations to disease, or that the
measures in expression systems do not entirely reflect
normal physiology. 
Many other explanations might account for the discrepan-
cies. These mutations might interfere with the ability of
CFTR to regulate other channels. For example, CFTR
activates ENaC in the duct [10], and if these mutations
interfered with that ability specifically, they could reduce
absorption of NaCl without affecting chloride conduc-
tance. The quality control mechanism might be more strin-
gent in the sweat duct epithelium, so that these mutant
proteins fail to reach the membrane in ducts, but not gen-
erally. The present model for NaCl absorption by the
sweat duct might be inadequate. Finally, the assay using
the dye MQAE may not be a reliable indicator of CFTR
chloride conductance. 
Because of these interesting issues, it will be important for
the experiments of Choi et al. [7] to be independently
repeated and extended. These issues do not detract from
the main finding, which calls attention to the importance
of CFTR’s involvement in bicarbonate transport. As others
have emphasized [20], bicarbonate is the body’s major
buffer, and contributes to physiological properties of great
relevance to cystic fibrosis, such as mucus viscoelasticity
[21] and pancreatic enzyme activity. Indeed, the experi-
ments of Choi et al. [7] have raised a host of new issues
about the functional role of CFTR, and further work along
the path they have opened is bound to deepen our under-
standing of how CFTR mutations cause disease. 
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